Should I buy or sell Plus Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSTV shares. View PSTV analyst ratings or view top-rated stocks .

What is Plus Therapeutics' stock price target for 2024?

1 brokers have issued 1-year price objectives for Plus Therapeutics' stock. Their PSTV share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 348.4% from the stock's current price. View analysts price targets for PSTV or view top-rated stocks among Wall Street analysts .

How have PSTV shares performed in 2023?

Plus Therapeutics' stock was trading at $4.7550 on January 1st, 2023. Since then, PSTV stock has decreased by 53.1% and is now trading at $2.23. View the best growth stocks for 2023 here .

Are investors shorting Plus Therapeutics?

Plus Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 215,000 shares, an increase of 441.6% from the October 31st total of 39,700 shares. Based on an average daily volume of 676,800 shares, the days-to-cover ratio is currently 0.3 days. Currently, 4.9% of the shares of the stock are sold short. View Plus Therapeutics' Short Interest .

When is Plus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our PSTV earnings forecast .

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) issued its quarterly earnings results on Tuesday, October, 31st. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.42. The company earned $1.24 million during the quarter, compared to the consensus estimate of $1.87 million. Plus Therapeutics had a negative trailing twelve-month return on equity of 421.08% and a negative net margin of 404.27%.

When did Plus Therapeutics' stock split?

Plus Therapeutics's stock reverse split on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD) , Trevena (TRVN) , Chimerix (CMRX) , Genocea Biosciences (GNCA) , Sorrento Therapeutics (SRNE) , Akero Therapeutics (AKRO) , Aldeyra Therapeutics (ALDX) , Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY) .

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Plus Therapeutics Stock Price, News & Analysis (NASDAQ:PSTV)

$2.23

+0.26 (+13.20%)

(As of 12/7/2023 ET)

Compare

Today's Range: $1.98
▼
$2.24
50-Day Range: $1.01
▼
$2.63
52-Week Range: $0.97
▼
$7.20

Volume: 79,376 shs
Average Volume: 211,222 shs
Market Capitalization: $10.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Plus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 348.4% Upside
$10.00 Price Target
Short Interest: Healthy
4.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$64,732 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($4.14) to ($0.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Plus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Plus Therapeutics has a forecasted upside of 348.4% from its current price of $2.23.
Amount of Analyst Coverage
Plus Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.86% of the float of Plus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Plus Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Plus Therapeutics has recently increased by 441.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Plus Therapeutics does not currently pay a dividend.
Dividend Growth
Plus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PSTV.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Plus Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for PSTV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Plus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $64,732.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.32% of the stock of Plus Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.54% of the stock of Plus Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Plus Therapeutics are expected to grow in the coming year, from ($4.14) to ($0.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Plus Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Plus Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Plus Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Plus Therapeutics Stock (NASDAQ:PSTV)

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PSTV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PSTV Stock News Headlines

December 1, 2023 | americanbankingnews.com

Head to Head Survey: Plus Therapeutics (NASDAQ:PSTV) and Accuray (NASDAQ:ARAY)

November 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

November 20, 2023 | msn.com

Fortress Biotech, Plus Therapeutics among healthcare movers

November 20, 2023 | finance.yahoo.com

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

November 15, 2023 | finance.yahoo.com

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

November 3, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)

November 3, 2023 | finance.yahoo.com

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

November 1, 2023 | benzinga.com

Why Plus Therapeutics Stock Popped Today

November 1, 2023 | finanznachrichten.de

Plus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

October 31, 2023 | finance.yahoo.com

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

October 25, 2023 | finance.yahoo.com

Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

October 23, 2023 | finance.yahoo.com

Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023

October 9, 2023 | finance.yahoo.com

Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October

September 19, 2023 | finance.yahoo.com

Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE

September 15, 2023 | finance.yahoo.com

Director Howard Clowes Buys 6,993 Shares of Plus Therapeutics Inc

September 11, 2023 | markets.businessinsider.com

JonesTrading Sticks to Its Buy Rating for Plus Therapeutics (PSTV)

September 11, 2023 | msn.com

Plus Therapeutics gets $1.9M advance payment from CPRIT

September 11, 2023 | finance.yahoo.com

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

September 9, 2023 | seekingalpha.com

Biocept gains on licensing pact with Plus Therapeutics for cancer test

September 8, 2023 | baystreet.ca

Plus Fails to Find Traction on Licensing Agreement

September 8, 2023 | msn.com

Biocept (NASDAQ:BIOC) Skyrockets on Licensing Deal with Plus Therapeutics

September 8, 2023 | finance.yahoo.com

Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?

September 8, 2023 | finance.yahoo.com

Plus Therapeutics Expands Biocept Partnership with Diagnostic Platform

September 8, 2023 | finance.yahoo.com

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

September 5, 2023 | finance.yahoo.com

Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase

See More Headlines

Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/31/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PSTV
CUSIP: N/A
CIK: 1095981
Web: www.plustherapeutics.com
Phone: 737-255-7194
Fax: 858-450-4335
Employees: 17
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $12.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +348.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($69.0230)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,270,000.00
Net Margins: -404.27%
Pretax Margin: -404.27%
Return on Equity: -421.08%
Return on Assets: -90.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.10
Quick Ratio: 1.10

Sales & Book Value

Annual Sales: $220,000.00
Price / Sales: 45.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.88 per share
Price / Book: 0.77

Miscellaneous

Outstanding Shares: 4,520,000
Free Float: 4,418,000
Market Cap: $10.08 million
Optionable: Not Optionable
Beta: 0.64

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Marc H. Hedrick M.B.A. (Age 60)
M.D., President, CEO & Director
Comp: $954.65k
Mr. Andrew J. Sims CPA (Age 50)
VP & CFO
Comp: $446.18k
Dr. Norman D. LaFrance FACNP (Age 75)
FACP, M.D., Chief Medical Officer & Senior VP
Comp: $637.81k
Ms. Desiree Smith (Age 59)
Corporate Controller, Principal Financial & Accounting Officer
Dr. John K. Fraser (Age 62)
Chief Scientist

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

PSTV Stock Analysis - Frequently Asked Questions

Should I buy or sell Plus Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSTV shares.
View PSTV analyst ratings or view top-rated stocks.
What is Plus Therapeutics' stock price target for 2024?: 1 brokers have issued 1-year price objectives for Plus Therapeutics' stock. Their PSTV share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 348.4% from the stock's current price.
View analysts price targets for PSTV or view top-rated stocks among Wall Street analysts.
How have PSTV shares performed in 2023?: Plus Therapeutics' stock was trading at $4.7550 on January 1st, 2023. Since then, PSTV stock has decreased by 53.1% and is now trading at $2.23.
View the best growth stocks for 2023 here.
Are investors shorting Plus Therapeutics?: Plus Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 215,000 shares, an increase of 441.6% from the October 31st total of 39,700 shares. Based on an average daily volume of 676,800 shares, the days-to-cover ratio is currently 0.3 days. Currently, 4.9% of the shares of the stock are sold short.
View Plus Therapeutics' Short Interest.
When is Plus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PSTV earnings forecast.

How were Plus Therapeutics' earnings last quarter?: Plus Therapeutics, Inc. (NASDAQ:PSTV) issued its quarterly earnings results on Tuesday, October, 31st. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.42. The company earned $1.24 million during the quarter, compared to the consensus estimate of $1.87 million. Plus Therapeutics had a negative trailing twelve-month return on equity of 421.08% and a negative net margin of 404.27%.
When did Plus Therapeutics' stock split?: Plus Therapeutics's stock reverse split on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Plus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY).
How do I buy shares of Plus Therapeutics?: Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PSTV) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Plus Therapeutics Stock Price, News & Analysis (NASDAQ:PSTV)

Plus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Plus Therapeutics Stock (NASDAQ:PSTV)

PSTV Stock Price History

PSTV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

PSTV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™